# Oath Peptides Product Quality: Purity, Endotoxin, and Catalog Coverage

> Oath Peptides reviews — per-compound product-quality analysis. 99.60% portfolio average, 99.93% peak (GLP2-T), 99.86% (SS-31), 99.66% (BPC-157 across ten batches), with USP <85> endotoxin passing on every visible batch.

**Pillar two — product quality**

Per-compound purity, endotoxin status, batch counts, and recency — drawn from the publicly searchable COA archive. Every number renders from a dated, sourced record.

**Pillar-two metrics**

- Portfolio avg: 99.60% (above industry norm, 199 batches)
- Peak purity: 99.93% (GLP2-T Tirzepatide, latest test 2026-05)
- BPC-157 purity: 99.66% (10 batches, latest test 2026-05)
- Endo status: All pass (every visible COA, USP <85>)

## The lead finding

Across the 199-batch archive, **99.60% portfolio average purity** is the headline number. Per-compound, the picture is dense and consistent. The GLP-1 monomer GLP2-T (Tirzepatide) tests at 99.93% across eight batches as of May 2026 — the peak of the visible catalog. The mitochondrial-targeted peptide SS-31 tests at 99.86% across four batches. The nootropic Selank tests at 99.71% across five batches. The most-tested compound in the visible archive, BPC-157, tests at 99.66% across ten batches. Two flagship blends — BPC-157 + TB-500 (WOLVERINE) at 99.39% across eight batches, and Tesamorelin + Ipamorelin at 99.43% across six batches — are tested at the same batch-level granularity as monomers. [public record verified]

Third-party comparator peptiderecon cites a 98-99.5% range across the catalog of approximately 40 peptides in its head-to-head supplier comparison. The narrower 99.39%-99.93% range in the visible Oath archive sits at the top of that band.

## Per-compound purity, batch counts, and endotoxin status

Table data drawn from the public COA archive as observed in the May 2026 snapshot. Every visible endotoxin test shows ENDO PASSED.

| Compound | Latest purity | Batches | Latest test | Endo | CAS |
|---|---|---|---|---|---|
| GLP2-T (Tirzepatide) | 99.93% | 8 | 2026-05 | Passed | 2023788-19-2 |
| SS-31 | 99.86% | 4 | 2026-05 | Passed | 736992-21-5 |
| Selank | 99.71% | 5 | 2026-05 | Passed | 129954-34-3 |
| BPC-157 | 99.66% | 10 | 2026-05 | Passed | 137525-51-0 |
| Tesamorelin + Ipamorelin blend | 99.43% | 6 | 2026-05 | Passed | 218949-48-5 / 170851-70-4 |
| BPC-157 + TB-500 (WOLVERINE) | 99.39% | 8 | 2026-05 | Passed | 137525-51-0 / 77591-33-4 |
| GLP3-R (Retatrutide) | Visible — RPS A1226 | — | 2026-04 | Visible — RPS audit | 2381089-83-2 |

## Average purity across the catalog

**99.60% average purity** across the 199 publicly archived batches as of May 2026. The per-compound highlights above show the distribution. The third-party reviewer peptiderecon cites a comparable 98-99.5% range across the catalog. The under-count of public COAs on RealPeptidesScores (142 indexed against Oath's actual 199) means even RPS's calculation is built on a thinner dataset than what Oath publishes. [public record verified]

## Blend testing as a structural signal

Batch-level testing of blended formulations is not always industry-standard. Many vendors test monomers and assume blends inherit the result, or run a single composite test per recipe. Oath Peptides tests blends at the same batch-level granularity as monomers — 8 WOLVERINE batches and 6 Tesamorelin + Ipamorelin batches in the visible window, each with its own COA and endotoxin pass/fail. The Tesamorelin + Ipamorelin batches `B0526` (dated 2026-05-05, accession `2605050019`, >99% purity HPLC-UV) and `66CBF` (2026-01-12) are independently visible on the RealPeptidesScores audit page — direct cross-verification of specific blend batches. The embedded vial photo on the RPS audit matches Oath brand labeling.

Wesley Y., reviewing at oath.reviews on 2026-04-30: "WOLVERINE blend arrived fast, vials filled correctly, COA posted for the lot." The structural commitment to per-batch blend testing is itself a quality signal — a vendor that did not have its blends consistently in spec would not invest in posting them individually.

## Catalog coverage: what Oath Peptides sells

The catalog visible in the public COA archive (selected examples from the May 2026 snapshot) spans multiple peptide classes: regenerative (BPC-157, BPC-157 + TB-500 WOLVERINE blend, BPC-157 + TB-500 + GHK-Cu blends, multi-peptide healing combinations), GLP-class metabolic (GLP2-T Tirzepatide, GLP3-R Retatrutide, semaglutide), growth-hormone-secretagogue (Tesamorelin + Ipamorelin blend), mitochondrial (SS-31), and nootropic (Selank). peptiderecon cites approximately 40 peptides total — narrower than the 50-150 catalogs at some competitors but covering the most clinically discussed compounds. peptideprotocolwiki notes Oath as "one of the few vendors with a complete GLP-1 lineup." [public record verified]

The narrower catalog is honestly enumerated by peptiderecon as a tradeoff against breadth-focused vendors. The editorial reading is that a tested-thoroughly, narrower catalog is a different value proposition from an untested-broader catalog. Different buyers will weight that differently; the dashboard frames both honestly.

## Honest gap: the visible catalog is a snapshot

The seven compounds tabulated above are not the complete catalog. The 2026-05-26 observation of the public COA archive captured these specific compounds at these specific test counts; new batches have shipped since, and other compounds in the catalog (additional GLP-1 monomers, additional regenerative blends, additional research-grade compounds) are not exhaustively captured here. The portfolio average (`99.60%`) and total batch count (`199`) reflect the entire archive at the observation date; per-compound highlights are a representative subset.

---

A trading-desk editorial reading of one research-peptide supplier's public testing record — independent, citation-explicit, and not for sale.